Breast cancer is a common malignancy in the United States, and is often treated with mastectomy followed by breast reconstruction. While there has been much focus on barriers for access to care around breast surgery, limited evidence exists regarding outcomes across race when these barriers are overcome. Quantifying how delayed breast cancer presentation impacts on breast cancer treatment among underserved populations has not been well elucidated. Clarifying whether there are differences in peri-operative outcomes across race can guide preoperative counseling as well as identify areas for continued improvement beyond initial access. The present study aims to evaluate patient comorbidity profiles, breast cancer characteristics, extirpative modalities, and reconstructive outcomes by race over five consecutive years of surgical outcomes at an academic medical center.
METHODS:
With institutional review board approval, records of all patients who underwent mastectomy with reconstruction at Yale New Haven Hospital between 2013 and 2017 were reviewed. Variables directly abstracted from patients' electronic medical records included patient demographics, comorbidities, operative variables, payer status, socioeconomic factors, and postoperative adverse outcomes.
RESULTS:
A total of 1,045 patients underwent 1,678 breast reconstructions during the five-year period. Mean age and standard deviation was 49.8 ± 10.6 years with a BMI of 27.9 ± 6.5. Hispanic and African-American patients had significantly higher mean BMI (p < 0.001) and higher rates of ASA class III or IV (p = 0.025). Furthermore, Hispanic and African-American patients had higher rates of obesity, diabetes, and hypertension (p < 0.001 for all three comparisons), higher rates of smoking (p = 0.003), and increased history of prior abdominal surgery (p = 0.007). Comparing oncologic characteristics, this population subset had higher rates of neoadjuvant chemotherapy (p = 0.036) and prior history of radiation (p = 0.016). Hispanic and African American patients were more likely to undergo modified radical mastectomy (p = 0.002) over nipple-sparing mastectomy (p = 0.035). Reconstructive complications revealed a higher overall complication rate (p = 0.023), higher rates of partial mastectomy flap necrosis (p = 0.043), as well as arterial (p = 0.009) and venous insufficiency (p = 0.026) during microvascular reconstruction among Hispanic and African American patients.
CONCLUSION:
Compared to other patients, the present study identifies higher comorbidity burdens, higher rates of prior radiation and neoadjuvant chemotherapy, and higher post-surgical complication rates among Hispanic and African American patients with breast cancer. While prior studies have noted poor access to care or reduced quality of care among some underserved racial groups, this study has identified persistent racial disparities despite comparable resources at a large academic center. 
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PURPOSE:
The opioid epidemic has gained significant national attention recently and the medical community is becoming more aware of the abuse potential and deleterious effects of opioid use, especially in surgical patients. Panniculectomy is a common plastic surgery procedure with a wide range of opioid use before and after surgery. In this study, we sought to evaluate the prevalence of preoperative opioid use among panniculectomy patients, and evaluate its impact on postoperative outcomes including complications, length of stay (LOS), and operative time.
METHODS:
We performed a retrospective review of patients 18 years of age or older who underwent panniculectomy at the Johns Hopkins Hospitals between March 2010 and May 2017. Patient charts were reviewed for demographic data and preoperative opioid use. Postoperative complications and persistent postoperative opioid use were examined at 30 days, six months, and 1 year postoperatively. Preoperative opioid use was assessed using home medication lists from their initial surgical consultation.
Pearson's chi squared test was used to assess factors associated with preoperative opioid use. Multivariate regression analysis was used to examine the association between opioid use and the risk of complications.
RESULTS:
Of the 203 patients included in this study, 40 (19.7%) had documented preoperative opioid use. There were no significant associations between preoperative opioid use and age, BMI, race, gender, ASA class, or comorbidities. Preoperative opioid users spent on average two more days in the hospital (coef: 2.11, 95% CI 0.329-3.89; p=0.02) and approximately 75 more minutes in the operating room (coef: 75; 95% CI: 23.9-126; p<0.005). There was a statistically significant association between preoperative opioid use and complications within 30 days after surgery (OR: 2.89; 95% CI: 1.27 -6.61, p=0.01) and within 180d after surgery (OR: 3.91; 95% CI: 1.33-11.5, p=0.01).
CONCLUSION:
Preoperative opioid use has been linked to worse postoperative outcomes in orthopedic and general surgery. This study suggests that preoperative opioid use is associated with increased odds of postoperative complications following panniculectomy within both 30 days and 180 days as well as longer lengths of stay and operative times. With these findings in mind, plastic surgeons should be aware of the potential consequences of preoperative opioid use and approach the issue with increased caution. 
INTRODUCTION:
Previous studies have attempted to elucidate risk factors in autologous breast reconstruction associated with wound complications and outcome with varying results. BMI is a risk factor that has been associated with a variety of reconstructive complications. Preoperative breast size has also been independently associated with infection and skin flap necrosis in expander-implant based reconstruction. However, there are few examinations of pre-operative breast dimensions and other comorbidities as a prognostic indicator of complications throughout various stages in the autologous breast reconstruction process.
METHODS:
A retrospective cohort analysis was performed on free-flap autologous breast reconstructions performed by two surgeons at a single institution from 2012-2018 (NTH, SST). Surgeries were divided into two groups based on post-operative complications: 1. No Complications and/or No Serious Complications (outpatient treatment), n=1239.2. Serious Complications requiring operative treatment or hospital admission, n=170.Complications at any point in the reconstruction process were considered: both after the tissue expander stage (if applicable), and also after the free flap reconstruction. Continuous variables were analyzed using t-tests. Binary variables were analyzed using Chi-Square (χ2) tests or Fisher's exact test for subgroups with n<5. Logistic multivariate regression analysis was performed to control for BMI. Data was collected using a centralized REDCap database. Statistical analysis was performed using R.
RESULTS:
Multivariate analysis after controlling for BMI demonstrated no statistically significant difference between groups for breast cup size (p>0.08), ptosis (p>0.066) and pre-operative breast dimensions (p>0.117). Patients with history of hypertension and previous surgical history of breast implant (p=0.013), tissue expander (p<0.01), breast reconstruction (p<0.01), oncologic breast surgery (p=0.026), and lumpectomy (p<0.01), were more likely to have at least one serious complication during the reconstruction process.
CONCLUSIONS:
This study provides clinical evidence that suggests increasing breast size is not correlated with increasing rates of serious complications, regardless of BMI, in free-flap autologous breast reconstruction after breast cancer. Rather, the results indicate that patients who have attempted previous breast reconstruction due to cancer are more likely to have serious complications. Whether this is due to an underlying biological susceptibility or the previous attempt at reconstruction is the root cause is worthy of further exploration. 
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